2026 Sponsors

BeyondSpring is a clinical-stage biopharmaceutical company developing first-in-class therapies addressing high unmet medical needs. Its lead asset, Plinabulin, in late-stage clinical development for NSCLC and other indications, acts as a dendritic cell maturation agent that supports both anti-cancer activity and immune modulation to resensitizing tumors resistant to checkpoint inhibitors.

Coherus Oncology is focused on developing and commercializing a diversified portfolio of next-generation immuno-oncology therapies that potentially extend patient survival across tumor types. The approval of LOQTORZI® (toripalimab-tpzi) and the advancement of multiple clinical stage immuno-oncology candidates targeting the tumor microenvironment underscore our commitment to immuno-oncology as a means for providing better treatment outcomes for patients with life-altering illnesses.

Immunai's engineering-first platform maps the immune system for the discovery and augmentation of novel therapeutics, through single-cell sequencing, functional genomics, big data and ML. Immunai holds a successful track record of partnering with leading pharmaceutical and biotech companies, academic institutions and hospitals to optimize their preclinical and clinical decision-making. To learn more, please visit https://www.immunai.com/

Onc.AI is venture-capital backed company committed to developing robust, clinically validated, imaging-AI powered clinical management solutions focused on immunotherapy optimization. Using patented, radiomic-based AI models, Onc.AI has developed a clinical decision support platform using routine diagnostic imaging scans specifically for planning and guidance of first-line immune checkpoint inhibitors (ICI) treatment plans. For more information, go to https://onc.ai/

Scimega is a niche Canadian oncology CRO acting in Canada within the context of global cutting-edge oncology trials sponsored by mid-size and smaller biotechs. Skilled in collaborative vendor teaming, Scimega guarantees sponsors the quickest site start-up and highest patient recruitment rate, without sacrificing premium quality data. With an optimal operations design robust enough to address an ever-changing clinical trial landscape, Scimega’s team of Lean Coached oncology experts go above-and-beyond to provide: Local, full-time, permanent hires for exceptional staff quality; An extensive network of Canadian Investigator Sites that frequently emerge among top enrollers, and are activated 50% faster than average for global studies; Optimal site engagement to maximize quality, timely data entry and query resolution; Robust and Lean Scimega methodology and processes are supported by current technology to keep every trial this CRO monitors on the Lean trajectory.

To learn more about the Canadian opportunity or explore an expansion with Scimega, please visit: https://scimega.com/

TD2 provides innovative services for improved and accelerated development of medicines for cancer. Our team has deep experience and understanding in drug development. Preclinical development, combined with regulatory affairs expertise, guides customized clinical trial design and execution. Our capabilities encourage the timely selection of patient populations who are most likely to benefit from a new agent, and the rapid identification of clinically significant endpoints. For more information, go to www.td2inc.com

Yunu provides medical research technology and services to life sciences companies and clinical research environments that perform precision imaging assessments. Yunu’s aim is to ensure breakthrough therapies are accessible to everyone by unifying medical imaging insights and connecting clinical communities. With thousands of clinical trials relying on the platform each day, Yunu is delivering a new standard of oncology trial management. For more information, go to www.yunu.io

For more information please visit https://www.zeiss.com/corporate/us/home.html

MERIT is an oncology endpoint expert providing image collection, centralized reading, and data management services for clinical trials since 2012. We have supported hundreds of trials across 58 countries. MERIT partners with CROs as well as pharma and biotech companies to deliver reliable endpoint services in global clinical trials. To learn more, please visit meritcro.com

Nona Biosciences specialized in fully human therapeutic antibody technology. Our proprietary Harbour Mice® technology are fully human transgenic mice platforms for either conventional fully human antibody (H2L2) or heavy chain only (HCAb) antibody discovery, engineering, and development. The HCAb platform is fully optimized and clinically validated with global patented protection.

OCCAM Immune is a non-profit Academic Research Organization emerging from Mount Sinai Hospital that provides immune monitoring services for clinical trials. Its streamlined process, from contracting to data delivery, and its one-stop shop approach—from sample processing to assays and data analysis—bridge academic research excellence with industrial scalability. For more information, go to https://occam-immune.com/

Ozette is a biotechnology company pioneering vertically integrated and computationally-driven solutions for deep immune profiling. By combining advanced AI-driven analysis with high quality & high-dimensional single-cell data generation in our Laboratory, Ozette is transforming immunological insights into actionable knowledge, empowering biopharmaceutical companies to develop precision therapies for complex diseases.

For more information, please visit https://www.ozette.com/

PredxBio, a TechBio company headquartered in Pittsburgh, is powering next-generation cancer therapeutics with its AI-driven spatial biomarkers, which delve into the mechanism of action of drugs and predict patient outcomes with over 90% accuracy. By transforming multiplexed biopsy images and multi-modal spatial data into actionable insights and revealing the network biology of cancer, PredxBio's SpaceIQ platform is setting new standards for biomarker discovery and clinical research. Partnering with top pharmaceutical companies, PredxBio is accelerating drug discovery and advancing personalized medicine to impact over 25 million cancer patients globally. For more information, visit www.predxbio.com.

RadMD is a full service, global imaging core lab for Phase 1-Phase 3.  Our oncology focus means expert, responsive teams who move quickly and are adaptable to your program.   Our industry leading reader group, managed by  medical & scientific affairs team continues to set higher standards for quality and innovation to meet demands of clinical development today. For more information, visit https://radmdimaging.com/

MedQIA, WorldCare Clinical and DARC, have come together to form Voiant, the industry’s leading clinical trial imaging solution provider with unparalleled scientific and clinical domain expertise. Voiant’s unique AI-based software platform integrates all aspects of clinical trial imaging, providing biopharmaceutical companies with high-speed delivery of quality clinical endpoint data. For more information, go to https://www.voiantclinical.com/

Picture Health creates multimodal AI biomarkers for precision oncology via our proprietary Px Platform with next-generation radiomics capabilities.  Our advanced radiomic and pathomic imaging features, demonstrated in over 80 peer reviewed papers, are tied to interpretable biological tumor characteristics. Picture Health partners with biopharma companies to improve patient characterization & selection using small datasets from Phase 1 and 2 clinical trials. The Px Platform enables us to develop custom predictive AI biomarkers tailored to a specific indication. For more information, go to https://picturehealth.com/

radiomics.bio is an AI-powered medical imaging and advanced statistics clinical research organisation, optimising the development of new oncology treatments. radiomics.bio supports biotech and pharma companies in all stages of clinical development offering services including disease characterization, dose impact quantification, response evaluation, image biomarker identification and outcome predictions. With radiomics.bio you can quantify response for objective decision making, obtain early insights from clinical trials, explore and validate drug mechanisms of action, and increase your understanding of disease on a patient, organ, or lesion level for insight-based decision making. For more information, go to www.radiomics.bio

RareCyte provides Precision Biology™ products and services for discovery, translational research and clinical diagnostics. The Orion™ spatial biology platform enables whole-slide highly multiplexed tissue analysis for multiple samples per day. Comprehensive liquid biopsy offerings enable CTC and other rare cell characterization and single cell retrieval for molecular analysis and CDx development. For more information, go to https://rarecyte.com/

For more information please visit https://www.7hillspharma.com/

For more information please visit https://abalos-tx.com/

For more information please visit https://www.oncoprecision.bio/

Vizenpistat (SR-8541!A), a new revolutionary cancer therapy, is a first checkpoint inhibitor for innate immunity restoration, needed in ½ of all cancers, in Ph2 clinicals.

TATUM Bioscience is redefining cancer treatment with multi-specific nanofilament immunotherapy. Our breakthrough technology boosts tumor visibility, restores immune function, and drives lasting antitumor responses—positioning TATUM at the forefront of next-generation immuno-oncology.

Virogin Biotech is a clinical-stage immuno-oncology company, with a primary focus on innovative HSV-1 based oncolytic virus (OV) and mRNA-based (including self-amplifying RNA/saRNA) therapeutics to elicit robust and durable anti-tumor immune response against solid tumors. Both the platforms exhibit a high degree of complementarity via a mechanism of heterologous prime-boost. Enhanced anti-tumor efficacy has been observed if OV and mRNA tumor vaccines were combined due to (1) modulation of immune-suppressive tumor microenvironment through release of immunological payloads carried by OV, and (2) antigen spread via direct tumor cell lysis triggered by OV infection, which functions like an in situ personalized tumor vaccine. Yet each platform has ‘plug-to-play' features to independently develop novel therapies against cancer & other indications. Our oncolytic HSV-1 platform has two candidates in clinical trials, with our most advanced asset in Phase 2. Candidates from our mRNA platform have also completed preclinical proof of concept.